March 24th 2023
Patients with metastatic squamous non–small cell lung cancer experienced a clinically meaningful survival benefit when treated with pembrolizumab in combination with chemotherapy.
January 26th 2023
Frontline Durvalumab Does Not Elicit Significant OS Improvement in Advanced, PD-L1-High NSCLCDecember 29th 2022
In the PEARL trial, monotherapy with durvalumab did not deliver a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with PD-L1-high stage IV non–small cell lung cancer.
Upfront Dostarlimab/Chemotherapy Yields Better Risk Reduction Than Pembrolizumab/Chemotherapy in NSCLCDecember 14th 2022
Patients with metastatic non-squamous non–small cell lung cancer who received frontline dostarlimab (Jemperli) plus chemotherapy experienced a risk of disease progression or death that was 30% greater than that experienced with pembrolizumab (Keytruda).
Adagrasib Receives Accelerated Approval for KRAS G12C Mutated NSCLCDecember 13th 2022
Adagrasib has received accelerated approval for KRAS G12C mutated non–small cell lung cancer. The prescribing label comes with warnings for gastrointestinal toxicities, QTC interval prolongation, hepatotoxicity, and interstitial lung disease.
First-Line Tremelimumab/Durvalumab/Chemotherapy May Become New Standard of Care in EGFR/ALK Wild-Type NSCLCNovember 22nd 2022
The combination of tremelimumab plus durvalumab plus chemotherapy, which was recently approved for patients with non–small cell lung cancer, could represent a new standard of care.
Osimertinib Still Holds The Crown in EGFR-Mutated Non-Small Cell Lung CancerNovember 19th 2022
As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.
Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC IndicationNovember 15th 2022
The FDA has given the go-ahead to a combination of tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for patients with non-small cell lung cancer and no EGFR mutations or ALK aberrations.
Oncology Drug Crash Course: Fam-Trastuzumab Deruxtecan-Nxki (Enhertu)November 8th 2022
After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.
Oncology Nurses Need Better Resources to Help Patients With Mental Health ProblemsOctober 4th 2022
Although oncology nurses are trained to show empathy and offer support, they lack the resources to adequately care for patients with acute mental health problems.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for PatientsSeptember 28th 2022
Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Nurse-Led Research Links Saturate Fatty Acids to Improved Immunotherapy Responses in NSCLCSeptember 23rd 2022
Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.